A stable analogue of prostacyclin that potently and selectively activates the IP receptor (Ki = 20 nM); the active form of the prodrug NS-398 that is stable in vivo, as plasma concentrations of MRE-269 remain near peak levels for more than eight hours; exhibits lower affinity for the vasoconstricting EP3 receptor than other IP receptor agonists.